A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers.

person Nataliya Volodymyrivna Uboha University of Wisconsin Carbone Cancer Center, Madison, WI info_outline Nataliya Volodymyrivna Uboha, Yvonne M. Saenger, Olatunji B. Alese, Dae Won Kim, Lei Zheng, Jorge Chaves, Siqing Fu, Jun Gong, Zhaohui Jin, John D. Powderly, Nashat Gabrail, Tanios S. Bekaii-Saab, Angela Tatiana Alistar, Christopher Chen, Laura Agensky, Apollina Goel, Steven Margossian, Steven N Quayle, Matteo Levisetti, J. Eva Selfridge

Authors person Nataliya Volodymyrivna Uboha University of Wisconsin Carbone Cancer Center, Madison, WI info_outline Nataliya Volodymyrivna Uboha, Yvonne M. Saenger, Olatunji B. Alese, Dae Won Kim, Lei Zheng, Jorge Chaves, Siqing Fu, Jun Gong, Zhaohui Jin, John D. Powderly, Nashat Gabrail, Tanios S. Bekaii-Saab, Angela Tatiana Alistar, Christopher Chen, Laura Agensky, Apollina Goel, Steven Margossian, Steven N Quayle, Matteo Levisetti, J. Eva Selfridge Organizations University of Wisconsin Carbone Cancer Center, Madison, WI, Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, Emory University Winship Cancer Institute, Atlanta, GA, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, Northwest Medical Specialties, LLC, Tacoma, WA, The University of Texas MD Anderson Cancer Center, Houston, TX, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, Mayo Clinic, Rochester, MN, Carolina BioOncology Institute, Huntersville, NC, Gabrail Cancer and Research Center, Canton, OH, Mayo Clinic Scottsdale, Scottsdale, AZ, Atlantic Health System, Carol G Simon Cancer Center, Morristown, NJ, Stanford University School of Medicine, Palo Alto, CA, Cue Biopharma, Inc., Boston, MA, Department of Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH Abstract Disclosures Research Funding CUE Biopharma Background: Immuno-STATs are modular fusion proteins designed for the selective activation of tumor antigen specific CD8+ T cells. CUE-102, the second Immuno-STAT in clinical trials, is composed of a human leukocyte antigen (HLA) complex, HLA-A*0201, a peptide epitope derived from the Wilms Tumor 1 (WT1) protein, and 4 molecules of reduced affinity human interleukin-2 (IL-2). In preclinical studies CUE-102 binds, activates and expands WT1-specific CD8+ T cells with the potential to enhance anti-tumor immunity in patients with WT1+ cancers. Here we present the results of the dose-finding portion (Part A) of the CUE-102-01 study. Methods: CUE-102-01 is a 2 part phase 1 study. HLA-A*02:01 positive patients with WT1+ advanced colorectal (CRC), gastric (GA) and gastroesophageal junction (GEJ), pancreatic (PDAC) or ovarian (OvCa) tumors refractory to standard therapies were eligible for participation. WT1 status is determined by IHC via central testing. CUE-102 monotherapy was administered intravenously every three weeks in doses ranging from 1 mg/kg to 8 mg/kg following 3+3 design rules with a Bayesian Logistic Regression Model overlay. Dose levels that exhibit an immune or tumor response may be expanded to further characterize activity and toxicity as allowed by safety rules. Results: Dose escalation was successfully completed in 28 patients with CRC (17), PDAC (6), GA/GEJ (3) and OvCa (2). No DLTs were observed. Three dose levels (2, 4 and 8 mg/kg) exhibited evidence of immune activity and were expanded up to 9 patients each for further evaluation. CUE-102 was well-tolerated with > 96% of treatment-related adverse events (TRAEs) grade ≤2. The most common TRAEs, were fatigue, infusion reactions, nausea and vomiting. There were no cases of CRS Grade ≥ 2. Preliminary PK data demonstrate dose dependent increases in exposure across the dose range assessed. Preliminary analysis of patient samples demonstrates selective expansion of WT1-specific CD8+ T cells. Stable disease of ≥ 6 weeks (range 6-36 weeks), as determined by RECIST 1.1, has been observed in 10 of 23 patients (DCR 43.5%). Conclusions: CUE-102 is a novel T cell engager that demonstrates acceptable tolerability, favorable PK, and supportive preliminary PD readouts. No DLTs or drug-related SAEs have been observed in doses up to 8 mg/kg as of the data cut-off. Adverse events have been manageable and consistent with the CUE-102 mechanism of action and underlying disease. Early signs of disease stabilization and anti-tumor activity in late-stage patients are encouraging. Part B is a dose expansion that further evaluates safety, PK/PD, recommended phase 2 dose (RP2D), antitumor efficacy and is currently enrolling patients. Clinical trial information: NCT05360680.

Clinical